Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

Transplantation Reviews

Volumn 30, Issue 3, 2016, Pages 119-143

  Torre Cisneros, J ^a,b   Aguado, J M ^b,c   Caston, J J ^b,d   Almenar, L ^e   Alonso, A ^f   Cantisan S ^a   Carratala J ^b,g   Cervera, C ^h   Cordero, E ^b,i   Farinas M C ^b,j   Fernandez Ruiz M ^c   Fortun J ^b,k   Frauca, E ^l   Gavalda J ^b,m   Hernandez D ⁿ   Herrero, I ^o   Len, O ^b,m   Lopez Medrano, F ^c   Manito, N ^p   Marcos, M A ^g   Martin Davila P ^k   Monforte, V ^m   Montejo, M ^q   Moreno, A ^g   Munoz P ^r   Navarro, D ^s,u   Perez Romero P ⁱ   Rodriguez Bernot, A ^t   Rumbao, J ^t   San Juan, R ^b,c   Vaquero, J M ^t   Vidal, E ^a,b   more..

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Universidad Complutense   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f UNIVERSITY OF A CORUÑA   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l HOSPITAL INFANTIL LA PAZ   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^o UNIVERSITY CLINIC OF NAVARRA   (Spain)

^p HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^q HOSPITAL DE CRUCES   (Spain)

^r HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^s HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^t HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^u UNIVERSITY OF VALENCIA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CD8 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; GANCICLOVIR; IMMUNOGLOBULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEW DRUG; VALACICLOVIR; VALGANCICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DRUG INDICATION; GENOTYPING TECHNIQUE; GOLD STANDARD; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LOW DRUG DOSE; ORGAN TRANSPLANTATION; PEDIATRICS; PNEUMONIA; PRACTICE GUIDELINE; PREEMPTIVE THEARPY; REVIEW; SALVAGE THERAPY; STANDARD; SYSTEMATIC REVIEW; TREATMENT DURATION; VACCINATION; VIRUS DIAGNOSIS; VIRUS LOAD;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; MONITORING, IMMUNOLOGIC; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; TRANSPLANT RECIPIENTS;

EID: 84964613516     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2016.04.001     Document Type: Review

References (321)

1. Torre-Cisneros J., Fortun J., Aguado J.M., et al. Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients. Enferm Infecc Microbiol Clin 2005, 23:424-437.
2. Torre-Cisneros J., Fariñas M.C., Castón J.J., et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infecion in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011, 29:735-758.
3. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Danziger-Isakov L., Humar A. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013, 96:333-360.
4. Schunemann H.J., Oxman A.D., Brozek J., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008, 336:1106-1110.
5. Guyatt G.H., Oxman A.D., Kunz R., et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008, 336:1170-1173.
6. Jaeschke R., Guyatt G.H., Dellinger P., et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008, 337:a744.
7. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., Schunemann H.J. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
8. Seed C.R., Piscitelli L.M., Maine G.T., et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 2009, 49:134-145.
9. Boaretti M., Sorrentino A., Zantedeschi C., Forni A., Boschiero L., Fontana R. Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients. J Clin Virol 2013, 56:124-128.
10. Piiparinen H., Hockerstedt K., Gronhagen-Riska C., Lautenschlager I. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004, 30:258-266.
11. Sanghavi S.K., Abu-Elmagd K., Keightley M.C., et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol 2008, 42:335-342.
12. Garrigue I., Doussau A., Asselineau J., et al. Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J Clin Microbiol 2008, 46:493-498.
13. Wolff D.J., Heaney D.L., Neuwald P.D., Stellrecht K.A., Press R.D. Multi-site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization: a report of the association for molecular pathology. J Mol Diagn 2009, 11:87-92.
14. Pang X.L., Fox J.D., Fenton J.M., Miller G.G., Caliendo A.M., Preiksaitis J.K. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9:258-268.
15. Hayden R.T., Yan X., Wick M.T., et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol 2012, 50:337-345.
16. Freyer J., Health A.B., Anderson R., Minor P.D. Coposed 1st WHO international standard for human cytomegalovirus for nucleic acid amplification-based assays. WHO/BS/10.2138, Geneva, Switzerland, 18-22 October 2010 2010, 1-40. the collaborative group.
17. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
18. Humar A., Gregson D., Caliendo A.M., et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999, 68:1305-1311.
19. Li H., Dummer J.S., Estes W.R., Meng S., Wright P.F., Tang Y.W. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol 2003, 41:187-191.
20. Hadaya K., Wunderli W., Deffernez C., et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol 2003, 41:3757-3764.
21. Hirsch H.H., Lautenschlager I., Pinsky B.A., et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013, 56:367-373.
22. Martin-Gandul C., Perez-Romero P., Sanchez M., et al. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol 2013, 56:13-18.
23. Razonable R.R., Asberg A., Rollag H., et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis 2013, 56:1546-1553.
24. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010, 23:689-712.
25. Fernandez-Ruiz M., Kumar D., Humar A. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. Clin Transl Immunol 2014, 3. 10.1038/cti.2014.3.
26. Boivin G., Goyette N., Rollag H., et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009, 14:697-704.
27. Komatsu T.E., Pikis A., Naeger L.K., Harrington P.R. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res 2014, 101:12-25.
28. Chou S. Approach to drug-resistant cytomegalovirus in transplant recipients. Curr Opin Infect Dis 2015, 28:293-299.
29. Chevillotte M., von Einem J., Meier B.M., Lin F.M., Kestler H.A., Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res 2010, 85:318-327.
30. Chou S., Ercolani R.J., Sahoo M.K., Lefterova M.I., Strasfeld L.M., Pinsky B.A. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother 2014, 58:4697-4702.
31. Chou S., Boivin G., Ives J., Elston R. Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. J Infect Dis 2014, 209:1219-1226.
32. Le Page A.K., Jager M.M., Kotton C.N., Simoons-Smit A., Rawlinson W.D. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013, 95:1455-1460.
33. Hodson E.M., Jones C.A., Webster A.C., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005, 365:2105-2115.
34. Small L.N., Lau J., Snydman D.R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006, 43:869-880.
35. Kalil A.C., Levitsky J., Lyden E., Stoner J., Freifeld A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005, 143:870-880.
36. Khoury J.A., Storch G.A., Bohl D.L., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006, 6:2134-2143.
37. Owers D.S., Webster A.C., Strippoli G.F., Kable K., Hodson E.M. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013, 2. 10.1002/14651858.CD005133.pub3.
38. Zhang L.F., Wang Y.T., Tian J.H., Yang K.H., Wang J.Q. Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials. Transpl Infect Dis 2011, 13:622-632.
39. Florescu D.F., Qiu F., Schmidt C.M., Kalil A.C. A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis 2014, 58:785-803.
40. Strippoli G.F., Hodson E.M., Jones C., Craig J.C. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006, 81:139-145.
41. Mumtaz K., Faisal N., Husain S., Morillo A., Renner E.L., Shah P.S. Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant 2015, 15:472-481.
42. Singh N., Wannstedt C., Keyes L., Gayowski T., Wagener M.M., Cacciarelli T.V. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005, 79:85-90.
43. Kielberger L., Bouda M., Jindra P., Reischig T. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kidney Blood Press Res 2012, 35:407-416.
44. Kalil A.C., Mindru C., Botha J.F., et al. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl 2012, 18:1440-1447.
45. Ramanan P., Razonable R.R. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother 2013, 45:260-271.
46. Bodro M., Sabe N., Llado L., et al. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl 2012, 18:1093-1099.
47. Harvala H., Stewart C., Muller K., Burns S., Marson L., MacGilchrist A., Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013, 85:893-898.
48. Roman A., Manito N., Campistol J.M., et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev 2014, 28:84-91.
49. Sambiase N.V., Higuchi M.L., Nuovo G., Gutierrez P.S., Fiorelli A.I., Uip D.E., Ramires J.A. CMV and transplant-related coronary atherosclerosis: an immunohistochemical, in situ hybridization, and polymerase chain reaction in situ study. Mod Pathol 2000, 13:173-179.
50. Duncan S.R., Paradis I.L., Dauber J.H., Yousem S.A., Hardesty R.L., Griffith B.P. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis 1992, 146:1213-1215.
51. Jaksch P., Zweytick B., Kerschner H., et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009, 28:670-675.
52. Kelly J.L., Albert R.K., Wood D.E., Raghu G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995, 59:1144-1147.
53. Kruger R.M., Paranjothi S., Storch G.A., Lynch J.P., Trulock E.P. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003, 22:754-763.
54. Palmer S.M., Grinnan D.C., Diane Reams B., Steele M.P., Messier R.H., Duane Davis R. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transpl 2004, 18:179-185.
55. Palmer S.M., Limaye A.P., Banks M., et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010, 152:761-769.
56. Weill D., Lock B.J., Wewers D.L., et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003, 3:492-496.
57. Lopez-Medrano F., Rueda B., Lizasoain M., et al. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients. Transpl Infect Dis 2009, 11:400-404.
58. Casillo R., Grimaldi M., Ragone E., et al. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients. Transplant Proc 2004, 36:651-653.
59. Egan J.J., Lomax J., Barber L., et al. Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 1998, 65:747-752.
60. Rayes N., Seehofer D., Kahl A., Kokott S., Pratschke J., Frei U., Neuhaus P. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis. Transpl Int 2007, 20:974-981.
61. Moreno A., Cervera C., Fortun J., et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl 2012, 18:70-81.
62. Balfour H.H., Chace B.A., Stapleton J.T., Simmons R.L., Fryd D.S. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989, 320:1381-1387.
63. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl J Med 1999, 340:1462-1470.
64. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008, 8:975-983.
65. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4:611-620.
66. Humar A., Lebranchu Y., Vincenti F., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10:1228-1237.
67. Kalil A.C., Sun J., Florescu D.F. IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis. Am J Transplant 2011, 11:18-21.
68. Humar A., Committee I.I.S., Peeters P., et al. Response to questions regarding the design and results of the IMPACT trial. Am J Transplant 2011, 11:177-178.
69. Rubin R.H., Kemmerly S.A., Conti D., et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000, 2:112-117.
70. Winston D.J., Busuttil R.W. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003, 75:229-233.
71. Hodson E.M., Ladhani M., Webster A.C., Strippoli G.F., Craig J.C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013, 2. 10.1002/14651858.CD003774.pub4.
72. Manuel O., Venetz J.P., Fellay J., et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly 2007, 137:669-676.
73. Hibberd P.L., Tolkoff-Rubin N.E., Conti D., et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995, 123:18-26.
74. Diaz-Pedroche C., Lumbreras C., San Juan R., et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006, 82:30-35.
75. Reischig T., Kacer M., Jindra P., Hes O., Lysak D., Bouda M. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. Clin J Am Soc Nephrol 2015, 10:294-304.
76. Barkholt L., Lewensohn-Fuchs I., Ericzon B.G., Tyden G., Andersson J. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis 1999, 1:89-97.
77. Gane E., Saliba F., Valdecasas G.J., O'Grady J., Pescovitz M.D., Lyman S., Robinson C.A. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The oral ganciclovir international transplantation study group [corrected]. Lancet 1997, 350:1729-1733.
78. Winston D.J., Busuttil R.W. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004, 77:305-308.
79. Kalil A.C., Freifeld A.G., Lyden E.R., Stoner J.A. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009, 4. 10.1371/journal.pone.0005512.
80. Shiley K.T., Gasink L.B., Barton T.D., Pfeiffenberger P., Olthoff K.M., Blumberg E.A. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 2009, 15:963-967.
81. Montejo M., Montejo E., Gastaca M., et al. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. Transplant Proc 2009, 41:2189-2191.
82. Winston D.J., Saliba F., Blumberg E., et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2012, 12:3021-3030.
83. Alain S., Revest M., Veyer D., et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 2013, 45:1603-1607.
84. Macdonald P.S., Keogh A.M., Marshman D., Richens D., Harvison A., Kaan A.M., Spratt P.M. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant 1995, 14:32-38.
85. Merigan T.C., Renlund D.G., Keay S., et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992, 326:1182-1186.
86. Aguado J.M., Gomez-Sanchez M.A., Lumbreras C., et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995, 39:1643-1645.
87. Valenza M., Czer L.S., Pan S.H., et al. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation. J Heart Lung Transplant 1995, 14:659-665.
88. Valantine H.A., Luikart H., Doyle R., et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001, 72:1647-1652.
89. Bonaros N.E., Kocher A., Dunkler D., et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 2004, 77:890-897.
90. Haddad F., Deuse T., Pham M., et al. Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant 2010, 29:306-315.
91. Cervera C., Pineda M., Linares L., et al. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Transplant Proc 2007, 39:2228-2230.
92. Lee S.O., Rim J.H., Sung H., et al. Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients. Transpl Infect Dis 2010, 12:31-37.
93. Gerbase M.W., Dubois D., Rothmeier C., Spiliopoulos A., Wunderli W., Nicod L.P. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 1999, 116:1265-1272.
94. Duncan S.R., Grgurich W.F., Iacono A.T., et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994, 150:146-152.
95. Zamora M.R., Nicolls M.R., Hodges T.N., Marquesen J., Astor T., Grazia T., Weill D. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004, 4:1635-1642.
96. Monforte V., Lopez C., Santos F., et al. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Am J Transplant 2009, 9:1134-1141.
97. Valentine V.G., Weill D., Gupta M.R., et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008, 27:875-881.
98. Horslen S.P. Optimal management of the post-intestinal transplant patient. Gastroenterology 2006, 130:S163-S169.
99. Pascher A., Kohler S., Neuhaus P., Pratschke J. Present status and future perspectives of intestinal transplantation. Transpl Int 2008, 21:401-414.
100. Fortun Abete J., Martin-Davila P., Moreno S., Quijano Y., de Vicente E., Pou L. Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation. Antimicrob Agents Chemother 2004, 48:2782-2783.
101. Ricart M.J., Malaise J., Moreno A., Crespo M., Fernandez-Cruz L. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005, 20:ii25-ii32. [ii62].
102. Becker B.N., Becker Y.T., Leverson G.E., Simmons W.D., Sollinger H.W., Pirsch J.D. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002, 39:1088-1095.
103. Luan F.L., Stuckey L.J., Park J.M., Kaul D., Cibrik D., Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009, 20:2449-2458.
104. Fallatah S.M., Marquez M.A., Bazerbachi F., et al. Cytomegalovirus infection post-pancreas-kidney transplantation - results of antiviral prophylaxis in high-risk patients. Clin Transpl 2013, 27:503-509.
105. Luan F.L., Kommareddi M., Ojo A.O. Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011, 11:1936-1942.
106. Luan F.L. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction. Transplant Proc 2013, 45:175-177.
107. Gabardi S., Asipenko N., Fleming J., et al. Evaluation of low- versus high-dose Valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Transplantation 2015.
108. Stevens D.R., Sawinski D., Blumberg E., Galanakis N., Bloom R.D., Trofe-Clark J. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis 2015.
109. Julian K.G., Shattahi E., Burg J.E., Boehmer J.P. Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients. Transplant Proc 2013, 45:3414-3417.
110. Weng F.L., Patel A.M., Wanchoo R., et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007, 83:290-296.
111. Sund F., Tufveson G., Dohler B., Opelz G., Eriksson B.M. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience. Nephrol Dial Transplant 2013, 28:758-765.
112. Humar A., Limaye A.P., Blumberg E.A., et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010, 90:1427-1431.
113. Paraskeva M., Bailey M., Levvey B.J., et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011, 11:2190-2196.
114. Schoeppler K.E., Lyu D.M., Grazia T.J., Crossno J.T., Vandervest K.M., Zamora M.R. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?. Am J Transplant 2013, 13:376-382.
115. Abu-Elmagd K.M., Costa G., Bond G.J., et al. Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg 2009, 250:567-579.
116. Bueno J., Green M., Kocoshis S., et al. Cytomegalovirus infection after intestinal transplantation in children. Clin Infect Dis 1997, 25:1078-1083.
117. Fryer J.P. Intestinal transplantation: current status. Gastroenterol Clin North Am 2007, 36:145-159. [vii].
118. Mazariegos G.V., Squires R.H., Sindhi R.K. Current perspectives on pediatric intestinal transplantation. Curr Gastroenterol Rep 2009, 11:226-233.
119. San Juan R., Prieto G., Lumbreras C., et al. Infection is the leading cause of death following small-bowel transplantation. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2010, EEUU, Boston, MA.
120. Kotton C.N., Kumar D., Caliendo A.M., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779-795.
121. Asberg A., Humar A., Rollag H., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7:2106-2113.
122. Singh N., Wannstedt C., Keyes L., et al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl 2008, 14:240-244.
123. Couzi L., Helou S., Bachelet T., et al. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012, 12:202-209.
124. Diaz-Pedroche C., Lumbreras C., Del Valle P., et al. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients. Transplant Proc 2005, 37:3766-3767.
125. Asberg A., Humar A., Jardine A.G., et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009, 9:1205-1213.
126. Humar A., Kumar D., Boivin G., Caliendo A.M. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002, 186:829-833.
127. Asberg A., Jardine A.G., Bignamini A.A., et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 2010, 10:1881-1888.
128. Eid A.J., Arthurs S.K., Deziel P.J., Wilhelm M.P., Razonable R.R. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010, 10:157-161.
129. Sia I.G., Wilson J.A., Groettum C.M., Espy M.J., Smith T.F., Paya C.V. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000, 181:717-720.
130. Witzke O., Hauser I.A., Bartels M., Wolf G., Wolters H., Nitschke M., Group V.S. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012, 93:61-68.
131. Martin-Gandul C., Perez-Romero P., Blanco-Lobo P., et al. D. Spanish network for research in infectious, viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy. Transpl Int 2014, 27:1060-1068.
132. Cantisan S., Lara R., Montejo M., et al. Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 2013, 13:738-745.
133. Manuel O., Husain S., Kumar D., et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013, 56:817-824.
134. Boillat Blanco N., Pascual M., Venetz J.P., Nseir G., Meylan P.R., Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 2011, 91:251-255.
135. Lisboa L.F., Preiksaitis J.K., Humar A., Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 2011, 92:1063-1068.
136. San Juan R., Aguado J.M., Lumbreras C., et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008, 47:875-882.
137. Hibberd P.L., Tolkoff-Rubin N.E., Cosimi A.B., et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992, 53:68-72.
138. Sagedal S., Nordal K.P., Hartmann A., et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000, 70:1166-1174.
139. Carbone J., Lanio N., Gallego A., et al. Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients. J Clin Immunol 2012, 32:809-819.
140. Sarmiento E., Fernandez-Yanez J., Munoz P., et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol 2005, 5:97-101.
141. Sarmiento E., Lanio N., Gallego A., et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol 2009, 9:649-652.
142. Lanio N., Sarmiento E., Gallego A., et al. Alterations of naive and memory B-cell subsets are associated with risk of rejection and infection in heart recipients. Transpl Int 2013, 26:800-812.
143. Sarmiento E., Diez P., Arraya M., Jaramillo J., Calahorra L., Fernandez-Yañez J. Hypogammaglobulinemia can be immunomodulated as a risk factor of infection in heart recipients by preventive use of intravenous immunoglobulin: results of a clinical trial. ISHLT 35th Annual Meeting and Scientific Sessions, Nice, France 2015.
144. Solidoro P., Delsedime L., Costa C., et al. Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation. New Microbiol 2011, 34:33-36.
145. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009, 22:76-98. [Table of Contents].
146. Egli A., Humar A., Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012, 55:1678-1689.
147. Gabanti E., Bruno F., Lilleri D., et al. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients. PLoS One 2014, 9. 10.1371/journal.pone.0106044.
148. Couzi L., Pitard V., Netzer S., et al. Common features of gammadelta T cells and CD8(+) alphabeta T cells responding to human cytomegalovirus infection in kidney transplant recipients. J Infect Dis 2009, 200:1415-1424.
149. Egli A., Silva M., O'Shea D., et al. An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients. PLoS One 2012, 7. 10.1371/journal.pone.0043937.
150. de Rham C., Hadaya K., Bandelier C., Ferrari-Lacraz S., Villard J. Expression of killer cell immunoglobulin-like receptors (KIRs) by natural killer cells during acute CMV infection after kidney transplantation. Transpl Immunol 2014, 31:157-164.
151. van Duin D., Avery R.K., Hemachandra S., et al. KIR and HLA interactions are associated with control of primary CMV infection in solid organ transplant recipients. Am J Transplant 2014, 14:156-162.
152. Wen Y., Monroe J., Linton C., et al. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 2014, 32:3796-3804.
153. Gimenez E., Blanco-Lobo P., Munoz-Cobo B., Solano C., Amat P., Perez-Romero P., Navarro D. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. J Gen Virol 2015, 96:2822-2831.
154. Sester M., Sester U., Gartner B., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001, 71:1287-1294.
155. Sester U., Gartner B.C., Wilkens H., et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005, 5:1483-1489.
156. Radha R., Jordan S., Puliyanda D., Bunnapradist S., Petrosyan A., Amet N., Toyoda M. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005, 5:110-117.
157. Bunde T., Kirchner A., Hoffmeister B., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005, 201:1031-1036.
158. Gerna G., Lilleri D., Fornara C., et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006, 6:2356-2364.
159. Eid A.J., Brown R.A., Arthurs S.K., Lahr B.D., Eckel-Passow J.E., Larson T.S., Razonable R.R. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl Int 2010, 23:506-513.
160. Gerna G., Lilleri D., Chiesa A., et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011, 11:2463-2471.
161. Pipeling M.R., John E.R., Orens J.B., Lechtzin N., McDyer J.F. Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J Infect Dis 2011, 204:1663-1671.
162. BenMarzouk-Hidalgo O.J., Cisneros J.M., Cordero E., et al. Therapeutic effect of the acquisition of CMV-specific immune response during pre-emptive treatment. Transplantation 2011, 91:927-933.
163. Lopez-Oliva M.O., Martinez V., Buitrago A., et al. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant. Transplantation 2014, 97:839-845.
164. Walker S., Fazou C., Crough T., et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis 2007, 9:165-170.
165. Kumar D., Chernenko S., Moussa G., et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009, 9:1214-1222.
166. Lisboa L.F., Kumar D., Wilson L.E., Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012, 93:195-200.
167. Abate D., Saldan A., Fiscon M., et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010, 202:585-594.
168. Costa C., Astegiano S., Terlizzi M.E., et al. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients. Transplant Proc 2011, 43:1159-1161.
169. Egli A., Binet I., Binggeli S., et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008, 6:29. 10.1186/1479-5876-6-29.
170. Abate D., Saldan A., Mengoli C., et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol 2013, 51:2501-2507.
171. Patel M., Stefanidou M., Long C.B., et al. Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant 2012, 16:18-28.
172. Bestard O., Lucia M., Crespo E., et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 2013, 13:1793-1805.
173. Engstrand M., Tournay C., Peyrat M.A., et al. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000, 69:2243-2250.
174. Sund F., Lidehall A.K., Claesson K., Foss A., Totterman T.H., Korsgren O., Eriksson B.M. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transpl 2010, 24:401-409.
175. La Rosa C., Krishnan A., Longmate J., et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008, 197:25-33.
176. Dirks J., Tas H., Schmidt T., Kirsch S., Gartner B.C., Sester U., Sester M. PD-1 analysis on CD28(-) CD27(-) CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients. Am J Transplant 2013, 13:3132-3141.
177. Li Pira G., Kern F., Gratama J., Roederer M., Manca F. Measurement of antigen specific immune responses: 2006 update. Cytometry B Clin Cytom 2007, 72:77-85.
178. Klenerman P., Cerundolo V., Dunbar P.R. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2002, 2:263-272.
179. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82:663-668.
180. Ling X., Xiong J., Liang W., et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 2012, 93:737-743.
181. Zeevi A., Husain S., Spichty K.J., et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007, 7:471-475.
182. Husain S., Raza K., Pilewski J.M., et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009, 87:1852-1857.
183. Ge S., Pao A., Vo A., et al. Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transpl Immunol 2011, 24:142-148.
184. De Paolis P., Favaro A., Piola A., et al. "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. Transplant Proc 2011, 43:1013-1016.
185. L.-M.F., Pérez-Jacoiste M.A., Aquilino C., et al. Functional monitoring of cell-mediated immune response predicts the ocurrence of cytomegalovirus (CMV) disease in kidney transplant (KT) recipients. 54th Annual Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC), September 6-9 2014.
186. Lucia M., Crespo E., Melilli E., et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clin Infect Dis 2014, 59:1537-1545.
187. Grundy J.E., Lui S.F., Super M., et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988, 2:132-135.
188. Hughes D., Hafferty J., Fulton L., et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol 2008, 41:92-95.
189. Atabani S.F., Smith C., Atkinson C., et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012, 12:2457-2464.
190. Shabir S., Kaul B., Pachnio A., et al. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation. J Am Soc Nephrol 2013, 24:1698-1708.
191. Bruminhent J., Thongprayoon C., Dierkhising R.A., Kremers W.K., Theel E.S., Razonable R.R. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?. Liver Transpl 2015, 21:539-546.
192. Manuel O. Clinical experience with immune monitoring for cytomegalovirus in solid-organ transplant recipients. Curr Infect Dis Rep 2013, 15:491-496.
193. Pass R.F., Zhang C., Evans A., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
194. Plotkin S.A., Starr S.E., Friedman H.M., et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991, 114:525-531.
195. Plotkin S.A., Higgins R., Kurtz J.B., et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994, 58:1176-1178.
196. Griffiths P.D., Stanton A., McCarrell E., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
197. Kharfan-Dabaja M.A., Boeckh M., Wilck M.B., et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.
198. Sagedal S., Nordal K.P., Hartmann A., et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002, 2:850-856.
199. Dickenmann M.J., Cathomas G., Steiger J., Mihatsch M.J., Thiel G., Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001, 71:764-767.
200. Sola R., Diaz J.M., Guirado L., et al. Significance of cytomegalovirus infection in renal transplantation. Transplant Proc 2003, 35:1753-1755.
201. Reischig T., Jindra P., Hes O., Bouda M., Kormunda S., Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009, 87:436-444.
202. Dzabic M., Rahbar A., Yaiw K.C., et al. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011, 53:969-976.
203. Gomez E., Laures A., Baltar J.M., Melon S., Diez B., de Ona M. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation. Transplant Proc 2005, 37:3760-3763.
204. Ozdemir F.N., Akgul A., Altunoglu A., Bilgic A., Arat Z., Haberal M. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc 2007, 39:990-992.
205. Hernandez D., Hanson E., Kasiske M.K., Danielson B., Roel J., Kasiske B.L. Cytomegalovirus disease is not a major risk factor for ischemic heart disease after renal transplantation. Transplantation 2001, 72:1395-1399.
206. Opelz G., Dohler B. Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients. Transplantation 2015, [Epub ahead of print]. 10.1097/TP.0000000000000522.
207. Einollahi B., Motalebi M., Salesi M., Ebrahimi M., Taghipour M. The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings. J Nephropathol 2014, 3:139-148.
208. Westall G.P., Michaelides A., Williams T.J., Snell G.I., Kotsimbos T.C. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003, 75:2064-2068.
209. Snyder L.D., Finlen-Copeland C.A., Turbyfill W.J., Howell D., Willner D.A., Palmer S.M. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010, 181:1391-1396.
210. Chmiel C., Speich R., Hofer M., Michel D., Mertens T., Weder W., Boehler A. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008, 46:831-839.
211. Johansson I., Martensson G., Nystrom U., Nasic S., Andersson R. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. BMC Infect Dis 2013, 13:582. 10.1186/1471-2334-13-582.
212. Manuel O., Kumar D., Moussa G., et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009, 87:719-725.
213. Tamm M., Aboyoun C.L., Chhajed P.N., Rainer S., Malouf M.A., Glanville A.R. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004, 170:1120-1123.
214. Evans P.C., Soin A., Wreghitt T.G., Taylor C.J., Wight D.G., Alexander G.J. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000, 69:30-35.
215. Burak K.W., Kremers W.K., Batts K.P., et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8:362-369.
216. Paya C.V., Wiesner R.H., Hermans P.E., et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 1992, 16:66-70.
217. van den Berg A.P., Klompmaker I.J., Hepkema B.G., et al. Cytomegalovirus infection does not increase the risk of vanishing bile duct syndrome after liver transplantation. Transpl Int 1996, 9:S171-S173.
218. Stern M., Hirsch H., Cusini A., et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014, 98:1013-1018.
219. Bosch W., Heckman M.G., Pungpapong S., Diehl N.N., Shalev J.A., Hellinger W.C. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation 2011, 93:723-728.
220. Chopra K.B., Demetris A.J., Blakolmer K., et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003, 76:1487-1491.
221. Teixeira R., Pastacaldi S., Davies S., et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000, 70:1454-1458.
222. Singh N., Wannstedt C., Keyes L., Wagener M.M., Gayowski T., Cacciarelli T.V. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005, 79:1428-1434.
223. Madalosso C., de Souza N.F., Ilstrup D.M., Wiesner R.H., Krom R.A. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998, 66:294-297.
224. Pastacaldi S., Teixeira R., Montalto P., Rolles K., Burroughs A.K. Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes. Liver Transpl 2001, 7:75-81.
225. Oh C.K., Pelletier S.J., Sawyer R.G., Dacus A.R., McCullough C.S., Pruett T.L., Sanfey H.A. Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation 2001, 71:767-772.
226. Bekker J., Ploem S., de Jong K.P. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant 2009, 9:746-757.
227. Fateh-Moghadam S., Bocksch W., Wessely R., Jager G., Hetzer R., Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003, 76:1470-1474.
228. Delgado J.F., Reyne A.G., de Dios S., et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2015, 34:1112-1119.
229. Potena L., Holweg C.T., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006, 82:398-405.
230. Potena L., Grigioni F., Magnani G., et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009, 28:461-467.
231. Zakliczynski M., Krynicka-Mazurek A., Pyka L., Trybunia D., Nadziakiewicz P., Przybylski R., Zembala M. The influence of cytomegalovirus infection, confirmed by pp65 antigen presence, on the development of cardiac allograft vasculopathy. Transplant Proc 2007, 39:2866-2869.
232. Zakliczynski M., Krynicka-Mazurek A., Konecka-Mrowka D., Nozynski J., Zeglen S., Przybylski R., Zembala M. Cytomegalovirus infection does not accelerate microvasculopathy development in heart transplant recipients. Transplant Proc 2009, 41:3219-3221.
233. Neidlinger N., Singh N., Klein C., et al. Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation. Am J Transplant 2010, 10:398-406.
234. Falagas M.E., Snydman D.R., George M.J., et al. Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG study group. Transplantation 1996, 61:1716-1720.
235. Peleg A.Y., Husain S., Qureshi Z.A., et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007, 44:1307-1314.
236. George M.J., Snydman D.R., Werner B.G., Griffith J., Falagas M.E., Dougherty N.N., Rubin R.H. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-study group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997, 103:106-113.
237. Fortun J., Martin-Davila P., Moreno S., et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002, 8:1065-1070.
238. Gavalda J., Len O., San Juan R., et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005, 41:52-59.
239. Manez R., Breinig M.C., Linden P., et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997, 176:1462-1467.
240. Saueressig M.G., Boussaud V., Amrein C., Guillemain R., Souilamas J., Souilamas R. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transpl 2011, 25:E430-E436.
241. Cantisan S., Torre-Cisneros J., Lara R., et al. Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation. Clin Vaccine Immunol 2009, 16:1429-1438.
242. Sagedal S., Hartmann A., Nordal K.P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004, 66:329-337.
243. Humar A., Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009, 9:S78-S86.
244. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
245. Posadas Salas M.A., Taber D.J., Chua E., Pilch N., Chavin K., Thomas B. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis 2013, 15:551-558.
246. Len O., Gavalda J., Aguado J.M., et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008, 46:20-27.
247. Razonable R.R. Strategies for managing cytomegalovirus in transplant recipients. Expert Opin Pharmacother 2010, 11:1983-1997.
248. Beam E., Dioverti V., Razonable R.R. Emerging cytomegalovirus management strategies after solid organ transplantation: challenges and opportunities. Curr Infect Dis Rep 2014, 16:419. 10.1007/s11908-014-0419-8.
249. Razonable R.R., Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013, 13:93-106.
250. Eid A.J., Arthurs S.K., Deziel P.J., Wilhelm M.P., Razonable R.R. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transpl 2008, 22:162-170.
251. Hantz S., Garnier-Geoffroy F., Mazeron M.C., et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 2010, 65:2628-2640.
252. Myhre H.A., Haug Dorenberg D., Kristiansen K.I., Rollag H., Leivestad T., Asberg A., Hartmann A. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011, 92:217-223.
253. Gracia-Ahufinger I., Gutierrez-Aroca J., Cordero E., et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation 2013, 95:1015-1020.
254. Mylonakis E., Kallas W.M., Fishman J.A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002, 34:1337-1341.
255. Pescovitz M.D. Maribavir: a new oral anti-cytomegalovirus drug. Futur Virol 2008, 3:435-443.
256. Winston D.J., Young J.A., Pullarkat V., et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008, 111:5403-5410.
257. Marty F.M., Ljungman P., Papanicolaou G.A., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011, 11:284-292.
258. Avery R.K., Marty F.M., Strasfeld L., et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010, 12:489-496.
259. Marty F.M., Winston D.J., Rowley S.D., et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013, 369:1227-1236.
260. Chemaly R.F., Ullmann A.J., Stoelben S., et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014, 370:1781-1789.
261. Kaul D.R., Stoelben S., Cober E., et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011, 11:1079-1084.
262. Ozaki K.S., Camara N.O., Nogueira E., et al. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients. Clin Transpl 2007, 21:675-680.
263. Sabe N., Gonzalez-Costello J., Rama I., et al. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors. Transpl Int 2012, 25:e78-e82.
264. Tedesco-Silva H., Felipe C., Ferreira A., et al. Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses. Am J Transplant 2015, 15:2655-2664.
265. Ciszek M., Mucha K., Foroncewicz B., Chmura A., Paczek L. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient - a case report. Ann Transplant 2014, 19:60-63.
266. Chacko B., John G.T. Leflunomide for cytomegalovirus: bench to bedside. Transpl Infect Dis 2012, 14:111-120.
267. Lau P.K., Woods M.L., Ratanjee S.K., John G.T. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011, 52:279. 10.1093/cid/ciq050.
268. Germi R., Mariette C., Alain S., et al. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res 2014, 101:57-61.
269. Sellar R.S., Peggs K.S. Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update. Expert Opin Biol Ther 2014, 14:1121-1126.
270. Peggs K.S. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther 2009, 9:725-736.
271. Macesic N., Langsford D., Nicholls K., et al. Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient. Am J Transplant 2015, 15:827-832.
272. Hebart H., Daginik S., Stevanovic S., et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002, 99:3830-3837.
273. Gratama J.W., van Esser J.W., Lamers C.H., Tournay C., Lowenberg B., Bolhuis R.L., Cornelissen J.J. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001, 98:1358-1364.
274. Feuchtinger T., Opherk K., Bethge W.A., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
275. Feucht J., Joachim L., Lang P., Feuchtinger T. Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr virus or adenovirus after allogeneic stem cell transplantation. Klin Padiatr 2013, 225:164-169.
276. Keenan R.D., Ainsworth J., Khan N., et al. Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers. Br J Haematol 2001, 115:428-434.
277. Neudorfer J., Schmidt B., Huster K.M., et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007, 320:119-131.
278. M. Assenmacher, M. Lohning, A. Radbruch, Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay, Curr Protoc Immunol, Chapter 6 (2002) [Unit 6] 27.
279. Brestrich G., Zwinger S., Fischer A., et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009, 9:1679-1684.
280. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110:1123-1131.
281. Camacho-Gonzalez A.F., Gutman J., Hymes L.C., Leong T., Hilinski J.A. 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation 2011, 91:245-250.
282. Green M., Michaels M.G., Katz B.Z., et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006, 6:1906-1912.
283. Danziger-Isakov L.A., Worley S., Michaels M.G., et al. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. Transplantation 2009, 87:1541-1548.
284. Martin J.M., Danziger-Isakov L.A. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation. Pediatr Transplant 2011, 15:229-236.
285. Lautenschlager I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Transpl Int 2009, 22:1031-1040.
286. Hocker B., Zencke S., Krupka K., et al. Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (Val-)ganciclovir. Transplantation 2015, 100:862-870.
287. Hussain T., Burch M., Fenton M.J., Whitmore P.M., Rees P., Elliott M., Aurora P. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007, 115:1798-1805.
288. Rha B., Redden D., Benfield M., Lakeman F., Whitley R.J., Shimamura M. Correlation and clinical utility of pp65 antigenemia and quantitative polymerase chain reaction assays for detection of cytomegalovirus in pediatric renal transplant patients. Pediatr Transplant 2012, 16:627-637.
289. Ritter M., Schmidt T., Dirks J., et al. Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies. Eur J Immunol 2013, 43:1099-1108.
290. Kumar D. Cellular immunity to CMV: advancing to the next level. Pediatr Transplant 2012, 16:539-541.
291. Danziger-Isakov L., Bucavalas J. Current prevention strategies against cytomegalovirus in the studies in pediatric liver transplantation (SPLIT) centers. Am J Transplant 2014, 14:1908-1911.
292. Danziger-Isakov L.A., Faro A., Sweet S., et al. Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: survey of eight pediatric lung transplant programs. Pediatr Transplant 2003, 7:469-473.
293. Fijo-Lopez-Viota J., Espinosa-Roman L., Herrero-Hernando C., Sanahuja-Ibanez M.J., Vila-Santandreu A., Praena-Fernandez J.M. Cytomegalovirus and paediatric renal transplants: is this a current issue?. Nefrologia 2013, 33:7-13.
294. Melgosa Hijosa M., Garcia Meseguer C., Pena Garcia P., Alonso Melgar A., Espinosa Roman L., Pena Carrion A., Navarro Torres M. Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Clin Nephrol 2004, 61:246-252.
295. Gerna G., Lilleri D., Callegaro A., Goglio A., Cortese S., Stroppa P., Torre G. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation. Transplantation 2008, 86:163-166.
296. Renoult E., Clermont M.J., Phan V., Buteau C., Alfieri C., Tapiero B. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Pediatr Transplant 2008, 12:420-425.
297. Madan R.P., Campbell A.L., Shust G.F., et al. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation 2009, 87:1318-1324.
298. Saitoh A., Sakamoto S., Fukuda A., et al. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation. Transplantation 2011, 92:930-935.
299. Spivey J.F., Singleton D., Sweet S., Storch G.A., Hayashi R.J., Huddleston C.B., Danziger-Isakov L.A. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr Transplant 2007, 11:312-318.
300. Bedel A.N., Hemmelgarn T.S., Kohli R. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir. Liver Transpl 2012, 18:347-354.
301. Vaudry W., Ettenger R., Jara P., Varela-Fascinetto G., Bouw M.R., Ives J., Walker R. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009, 9:636-643.
302. Lapidus-Krol E., Shapiro R., Amir J., Davidovits M., Steinberg R., Mor E., Avitzur Y. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Pediatr Transplant 2010, 14:753-760.
303. Venturi C., Bueno J., Gavalda J., et al. Impact of valganciclovir on Epstein-Barr virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transplant Proc 2009, 41:1038-1040.
304. Vethamuthu J., Feber J., Chretien A., Lampe D., Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007, 11:301-305.
305. Villeneuve D., Brothers A., Harvey E., Kemna M., Law Y., Nemeth T., Gantt S. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant 2013, 17:80-85.
306. Asberg A., Bjerre A., Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant 2014, 18:103-111.
307. Martin M., Goyette N., Ives J., Boivin G. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J Clin Virol 2010, 47:321-324.
308. Hocker B., Zencke S., Pape L., et al. Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation. Am J Transplant 2016, 16:921-929.
309. Weseslindtner L., Kerschner H., Steinacher D., et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant 2012, 12:2172-2180.
310. Painter W., Robertson A., Trost L.C., Godkin S., Lampert B., Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012, 56:2726-2734.
311. Beadle J.R., Hartline C., Aldern K.A., Rodriguez N., Harden E., Kern E.R., Hostetler K.Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002, 46:2381-2386.
312. James S.H., Price N.B., Hartline C.B., Lanier E.R., Prichard M.N. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother 2013, 57:3321-3325.
313. Lischka P., Hewlett G., Wunberg T., et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010, 54:1290-1297.
314. Goldner T., Zimmermann H., Lischka P. Phenotypic characterization of two naturally occurring human cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. Antiviral Res 2015, 116:48-50.
315. Goldner T., Hewlett G., Ettischer N., Ruebsamen-Schaeff H., Zimmermann H., Lischka P. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011, 85:10884-10893.
316. Biron K.K., Harvey R.J., Chamberlain S.C., et al. Potent and selective inhibition of human cytomegalovirus replication by 1263 W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob Agents Chemother 2002, 46:2365-2372.
317. Pescovitz M.D., Bloom R., Pirsch J., Johnson J., Gelone S., Villano S.A. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transplant 2009, 9:2324-2330.
318. Ma J.D., Nafziger A.N., Villano S.A., Gaedigk A., Bertino J.S. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3a, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother 2006, 50:1130-1135.
319. F.D., Mullane K.M., Kwak E., et al. Brincidofovir (CMX001) experience in renal transplant patients for treatment of refractory CMV infection (abstract D2364), American Transplant Congress; San Francisco, USA 2014.
320. Stoelben S., Arns W., Renders L., et al. Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 2014, 27:77-86.
321. Strasfeld L., Lee I., Tatarowicz W., Villano S., Chou S. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010, 202:104-108.